Trial Profile

Open Label Extension Protocol (Japan):Assess the Efficacy and Safety of Beremagene Geperpavec (B-VEC, previously KB103) for the Treatment of Japanese Patients with Dystrophic Epidermolysis Bullosa (DEB)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Aug 2025 According to Krystal Biotech media release, results of OLE study of VYJUVEK in Japanese DEB patients were published in the Journal of Dermatology.
04 Aug 2025 According to a Krystal Biotech media release, VYJUVEK has been approved by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of DEB. The company is on track to launch in Japan before the end of 2025.
16 Jul 2025 Results published in the Journal of Dermatology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com